ABOS 250117 10.00C (ABOS250117C10000) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Jan 10 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Jan 9 13:32

Update Thursday 1/9/25

$Acumen Pharmaceuticals (ABOS.US)$ Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
GlobeNewswire· 08:0011mins
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer's disease (AD)
Sabirnetug demonstrated selectiv...

Jaguar8

Jan 9 08:04

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
1 hour ago, 5:00 AM PST
Via GlobeNewswire
ABOS
Share
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer's disease (AD)
Sabirnetug demonstrated ...

Jaguar8

Oct 31, 2024 07:20

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease
Acumen Pharmaceuticals presented data on using pTau217 assay as an efficient screening tool for their Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer's disease. The assay, with a threshold of ≥0.15 pg/mL, effectively identifie...

Stock_Drift

Oct 23, 2024 15:45

After Hours Ticks. 4:44pm

$Rimini Street (RMNI.US)$ $Acumen Pharmaceuticals (ABOS.US)$ $Molina Healthcare (MOH.US)$ $BioVie (BIVI.US)$ $Allakos (ALLK.US)$ $CNS Pharmaceuticals (CNSP.US)$ $GraniteShares 2x Long TSLA Daily ETF (TSLR.US)$ $Direxion Daily TSLA Bull 2X Shares (TSLL.US)$ $T-Rex 2x Long Tesla Daily Target ETF (TSLT.US)$ $Twin Vee PowerCats (VEEE.US)$ $EpicQuest Education (EEIQ.US)$ $Mobile-health Network Solutions (MNDR.US)$
📊⚡️📊

Jaguar8

Jul 28, 2024 07:08

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024.
The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring s...